ugg Guggenheim Begins Coverage on Dermira (DERM)

December 17, 2017

ugg

ugg Guggenheim Begins Coverage on Dermira (DERM)-1Guggenheim assumed coverage on shares of Dermira (NASDAQ:DERM) in a research note published on Tuesday, December 5th, MarketBeat reports. The brokerage issued a buy rating on the biopharmaceutical company’s stock.

A number of other research firms have also recently commented on DERM. Cantor Fitzgerald reiterated a buy rating and set a $45.00 price target on shares of Dermira in a report on Monday, November 6th. Zacks Investment Research cut Dermira from a hold rating to a sell rating in a report on Thursday, November 9th. Leerink Swann restated an outperform rating and set a $41.00 price objective (down previously from $47.00) on shares of Dermira in a report on Tuesday, November 7th. Mizuho restated a buy rating and set a $43.00 price objective (up previously from $40.00) on shares of Dermira in a report on Thursday, September 7th. Finally, BidaskClub upgraded Dermira from a sell rating to a hold rating in a report on Saturday, December 2nd. Four equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. Dermira has an average rating of Hold and an average price target of $41.00.

Shares of Dermira (NASDAQ:DERM) opened at $27.06 on Tuesday. Dermira has a 12 month low of $21.35 and a 12 month high of $38.75. The company has a debt-to-equity ratio of 1.40, a quick ratio of 4.68 and a current ratio of 4.68.

In other news, insider Eugene A. Bauer sold 7,500 shares of the company’s stock in a transaction dated Wednesday, October 11th. The shares were sold at an average price of $30.04, for a total transaction of $225,300.00. The ugg australia sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Thomas G. Wiggans sold 5,000 shares of the company’s stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $27.51, for a total transaction of $137,550.00. The disclosure for this ugg australia sale can be found here. In the last ninety days, insiders have sold 33,800 shares of company stock worth $946,975. Insiders own 13.30% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. AXA raised its holdings in shares of Dermira by 41.5% in the 3rd quarter. AXA now owns 300,333 shares of the biopharmaceutical company’s stock worth $8,109,000 after acquiring an additional 88,079 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Dermira in the 3rd quarter worth about $696,000. Point72 Asset Management L.P. raised its holdings in shares of Dermira by 621.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 712,904 shares of the biopharmaceutical company’s stock worth $19,248,000 after acquiring an additional 614,138 shares during the last quarter. Alyeska Investment Group L.P. raised its holdings in shares of Dermira by 1.8% in the 3rd quarter. Alyeska Investment Group L.P. now owns 351,059 shares of the biopharmaceutical company’s stock worth $9,479,000 after acquiring an additional 6,270 shares during the last quarter. Finally, Platinum Investment Management Ltd. raised its holdings in shares of Dermira by 60.1% in the 3rd quarter. Platinum Investment Management Ltd. now owns 92,400 shares of the biopharmaceutical company’s stock worth $2,494,000 after acquiring an additional 34,700 shares during the last quarter. Hedge funds and other institutional investors own 99.54% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://stocknewstimes.com/2017/12/16/dermira-derm-coverage-initiated-at-guggenheim.html.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

ugg Guggenheim Begins Coverage on Dermira (DERM)-2

Thank you for taking the time to read this article. I hope you like it

ugg .

Leave a Reply

Your email address will not be published. Required fields are marked *